Advances in chronic kidney disease最新文献_第10页

Acute Kidney Injury in Patients With Cancer: A Review of Onconephrology 肿瘤患者急性肾损伤:肿瘤学综述

IF 2.9 3区医学

Advances in chronic kidney disease Pub Date : 2021-09-01 DOI: 10.1053/j.ackd.2021.09.008

Prakash Gudsoorkar , Amit Langote , Palavi Vaidya , Alejandro Y. Meraz-Muñoz

引用次数: 2

Tumor Lysis Syndrome 肿瘤溶解综合征

IF 2.9 3区医学

Advances in chronic kidney disease Pub Date : 2021-09-01 DOI: 10.1053/j.ackd.2021.09.007

Tarek Barbar, Insara Jaffer Sathick

引用次数: 7

Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes 胰高血糖素样肽-1受体激动剂治疗2型糖尿病患者的肾脏预后

IF 2.9 3区医学

Advances in chronic kidney disease Pub Date : 2021-07-01 DOI: 10.1053/j.ackd.2021.04.005

Ofri Mosenzon , Meir Schechter , Gil Leibowitz

{"title":"Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes","authors":"Ofri Mosenzon , Meir Schechter , Gil Leibowitz","doi":"10.1053/j.ackd.2021.04.005","DOIUrl":"10.1053/j.ackd.2021.04.005","url":null,"abstract":"<div><p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective in reducing glycemia in patients with type 2 diabetes (T2D). These medications effectively reduce cardiovascular (CV) risk in patients with T2D and established CV disease or with multiple risk factors. In addition, treatment with GLP-1 RA may exert protective effects on the diabetic kidney. Herein, we summarize the findings regarding the kidney safety and efficacy of GLP-1 RAs in patients with T2D. We review data from GLP-1 RAs phase 3 kidney studies, CV outcome trials, as well as real-world evidence. The accumulating data show that treatment with GLP-1 RAs is safe, well-tolerated, and effective in patients with different levels of kidney dysfunction. Furthermore, CV outcome trials suggest that GLP-1 RAs reduce albuminuria and may attenuate the decline in kidney function over time. The ongoing FLOW trial studying the effects of semaglutide in patients with diabetic kidney disease is expected to shed light on the effects of GLP-1 RAs on kidney outcomes and clarify their role in the management of patients with T2D and kidney disease.</p></div>","PeriodicalId":7221,"journal":{"name":"Advances in chronic kidney disease","volume":"28 4","pages":"Pages 347-360"},"PeriodicalIF":2.9,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1548559521000380/pdfft?md5=258c753d4cb626b81de4603db7a133c3&pid=1-s2.0-S1548559521000380-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39736939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Treatment of Diabetic Nephropathy: Changing Landscapes and New Horizons 糖尿病肾病的治疗:变化的景观和新的视野

IF 2.9 3区医学

Advances in chronic kidney disease Pub Date : 2021-07-01 DOI: 10.1053/j.ackd.2021.11.001

Charuhas V. Thakar MD

引用次数: 2

Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People With and Without Diabetes 钠-葡萄糖共转运蛋白2抑制:糖尿病患者和非糖尿病患者肾脏和心血管保护的基本原理和机制

IF 2.9 3区医学

Advances in chronic kidney disease Pub Date : 2021-07-01 DOI: 10.1053/j.ackd.2021.02.006

Carol Pollock , Brendon L. Neuen

{"title":"Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People With and Without Diabetes","authors":"Carol Pollock , Brendon L. Neuen","doi":"10.1053/j.ackd.2021.02.006","DOIUrl":"10.1053/j.ackd.2021.02.006","url":null,"abstract":"<div><p>Large-scale randomized trials have demonstrated the remarkable capacity of sodium-glucose cotransporter 2 inhibitors to reduce the risk of cardiovascular outcomes and kidney disease progression, irrespective of the presence or absence of type 2 diabetes mellitus. Although the results of these trials have transformed clinical practice guidelines, the mechanisms underpinning the wide-ranging benefits of this class of agents remain incompletely understood and subject to ongoing investigation. Improvements in cardiometabolic risk factors such as glucose, blood pressure, body weight, and albuminuria likely contribute. However, other direct effects on physiological and cellular function, such as restoration of tubuloglomerular feedback, improvements in kidney and cardiac oxygenation and energy efficiency, as well as restoration of normal autophagy are also likely to be important. This review summarizes the rationale and potential mechanisms for cardiorenal protection with sodium-glucose cotransporter 2 inhibitors in people with and without diabetes, their relative importance, and the experimental and clinical lines of evidence supporting these hypotheses.</p></div>","PeriodicalId":7221,"journal":{"name":"Advances in chronic kidney disease","volume":"28 4","pages":"Pages 298-308"},"PeriodicalIF":2.9,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1548559521000082/pdfft?md5=96c6761140cda570cfd1099e0aa2771e&pid=1-s2.0-S1548559521000082-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39736935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Novel Anti-inflammatory and Anti-fibrotic Agents for Diabetic Kidney Disease—From Bench to Bedside 治疗糖尿病肾病的新型抗炎抗纤维化药物——从实验到临床

IF 2.9 3区医学

Advances in chronic kidney disease Pub Date : 2021-07-01 DOI: 10.1053/j.ackd.2021.09.010

Susanne B. Nicholas

{"title":"Novel Anti-inflammatory and Anti-fibrotic Agents for Diabetic Kidney Disease—From Bench to Bedside","authors":"Susanne B. Nicholas","doi":"10.1053/j.ackd.2021.09.010","DOIUrl":"10.1053/j.ackd.2021.09.010","url":null,"abstract":"<div><p>Chronic low-grade inflammation, now coined by the new paradigm as “metaflammation” or “metainflammation”, has been linked to chronic kidney disease and its progression. In diabetes, altered metabolism denotes factors associated with the metabolic syndrome and hyperglycemia, among others. The interplay among hyperglycemia, oxidative stress, and inflammation in the pathogenesis of diabetic kidney disease (DKD) has been broadly explored. Identification of mediators of inflammatory processes involving macrophage infiltration, production of inflammasomes, release of cytokines, and activation of pertinent signaling pathways including mitogen-activated protein kinase, Jun N-terminal kinase, Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway (JAK/STAT), and apoptosis signal-regulating kinase 1 signaling mechanisms have enabled the development of therapeutic agents for DKD. This review describes the evidence supporting the contribution of the inflammatory response and fibrotic changes and focuses on selected, novel, promising drugs as well as repurposed drugs that have made it to phase 2, 3, or 4 of clinical trials in adults with type 2 diabetes mellitus and their potential to become an important part of our armamentarium to improve the management of DKD. Importantly, drugs that solely target inflammatory processes may be insufficient to fully optimize care of patients with DKD because of the complex nature of the disease.</p></div>","PeriodicalId":7221,"journal":{"name":"Advances in chronic kidney disease","volume":"28 4","pages":"Pages 378-390"},"PeriodicalIF":2.9,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1548559521000999/pdfft?md5=36f969efe4606138d3028077317eecf9&pid=1-s2.0-S1548559521000999-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39737375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Mineralocorticoid Receptor Antagonists—Evidence for Kidney Protection, Trials With Novel Agents 矿皮质激素受体拮抗剂-肾脏保护的证据，新药物的试验

IF 2.9 3区医学

Advances in chronic kidney disease Pub Date : 2021-07-01 DOI: 10.1053/j.ackd.2021.07.005

Omar Al Dhaybi, George L. Bakris

引用次数: 1

Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation 新型降血糖疗法在实体器官移植中的应用

IF 2.9 3区医学

Advances in chronic kidney disease Pub Date : 2021-07-01 DOI: 10.1053/j.ackd.2021.03.001

Pitchaphon Nissaisorakarn, Martha Pavlakis, Amtul Aala

引用次数: 1

NKF 2022 Spring Clinical Meetings Physician Program NKF 2022春季临床会议医师计划

IF 2.9 3区医学

Advances in chronic kidney disease Pub Date : 2021-07-01 DOI: 10.1053/S1548-5595(21)00172-5

引用次数: 0

What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice? 到目前为止，我们从钠-葡萄糖共转运蛋白2抑制剂在临床实践中的应用中学到了什么?

IF 2.9 3区医学

Advances in chronic kidney disease Pub Date : 2021-07-01 DOI: 10.1053/j.ackd.2021.06.002

Peter Rossing , Frederik Persson

{"title":"What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?","authors":"Peter Rossing , Frederik Persson","doi":"10.1053/j.ackd.2021.06.002","DOIUrl":"10.1053/j.ackd.2021.06.002","url":null,"abstract":"<div><p>Since the introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors, the aim of this therapy has expanded from being solely a glucose-lowering treatment into also being organ protective even in people without diabetes. In this review, we present this evolution of the treatment principle, from early studies over randomized controlled trials. We discuss available real-world evidence and summarize a number of recent post hoc analyses from the randomized controlled trials with kidney end points. As the use of sodium-glucose cotransporter 2 inhibitors becomes more widespread, new questions arise regarding initiation and follow-up, which we try to answer by providing the currently available data. For translation of study results to global effects, implementation becomes important. As is often the case, this does not happen without barriers, which must be addressed and handled. Finally, future studies and populations are discussed because it may well be that sodium-glucose cotransporter 2 inhibition are expanding into further areas.</p></div>","PeriodicalId":7221,"journal":{"name":"Advances in chronic kidney disease","volume":"28 4","pages":"Pages 290-297"},"PeriodicalIF":2.9,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1548559521000410/pdfft?md5=0c299bac98f8a2e72ba922ba52801385&pid=1-s2.0-S1548559521000410-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39736934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0